The hand-foot syndrome - A frequent secondary manifestation in antineoplastic chemotherapy

European Journal of Dermatology

Volumn 16, Issue 5, 2006, Pages 494-499

  Janusch, M ^a   Fischer, M ^a   Marsch, W Ch ^a   Holzhausen, H J ^a   Kegel, T ^a   Helmbold, P ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Differential diagnosis; Hand foot syndrome; Immunohistology; Palmoplantar erythrodysesthesia; Transmission electron microscopy

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTARABINE; CYTOSTATIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; DIMETHYL SULFOXIDE; DISINFECTANT AGENT; DOCETAXEL; DOXORUBICIN; EMITEFUR; ESTRAMUSTINE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; GLUCOCORTICOID; IRINOTECAN; MITOTANE; NAVELBINE; NICOTINE PATCH; OXALIPLATIN; PYRIDOXINE; SORAFENIB; TEGAFUR; UFT; URACIL;

ADRENAL CORTEX CARCINOMA; ALLERGIC RASH; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOMA; CONTACT DERMATITIS; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; ERYTHEMA MULTIFORME; GRAM NEGATIVE INFECTION; HAND FOOT AND MOUTH DISEASE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERHIDROSIS; INCIDENCE; KERATINOCYTE; KERATOSIS; LYMPHOCYTIC INFILTRATION; MYCOSIS; PROSTATE CARCINOMA; RASH; REVIEW; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; ERYTHEMA; FLUOROURACIL; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; INCIDENCE; PARESTHESIA; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 33845269828     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0041     Document Type: Review

References (29)

1. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148: 90-2.
2. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-9.
3. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-7.
4. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.Meta-Analysis Group In Cancer. J Clin Oncol 1998; 16: 3537-41.
5. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136: 1475-80.
6. Baack BR, Burgdorf WH. Chemotherapyinduced acral erythema. J Am Acad Dermatol 1991; 24: 457-61.
7. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, Von-Roenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169-73.
8. Levine LE, Medenica MM, Lorincz AL. Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985; 121: 102-4.
9. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14: 1735-43.
10. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82: 965-9.
11. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer. Invest New Drugs 2002; 20: 101-4.
12. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Huntingt) 2002; 16: 31-7.
13. Dickson NR, Nicholson BP, Hande K, Blanke C, Johnson D, Cohen A. Paclitaxel, UFT, and calcium folinate in metastatic breast cancer. Oncology (Huntingt) 1999; 13: 69-70.
14. Fitzpatrick JE. The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 1993; 20: 1-14.
15. Cohen PR. Acral erythema: A clinical review. Cutis 1993; 51: 175-9.
16. Park YH, Ryoo BY, Lee HJ, Kim SA, Chung JH. High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy. Ann Oncol 2003; 14: 1691-2.
17. Hoff PM, Pazdur R, Benner SE, Canetta R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1998; 9: 479-90.
18. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Huntingt) 1998; 12: 23-7.
19. Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004; 18: 1161-8; (73; discussion 73-6, 81-4).
20. Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989; 111: 688-9.
21. Kingsley EC. 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994; 120: 813.
22. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999; 44: 303-6.
23. Jucgla A, Sais G, Navarro M. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131: 364-5.
24. Nemunaitis J, Eager R, Twaddell T. Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. J Clin Oncol 2000; 18: 3423-34.
25. Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 2001; 24: 353-67.
26. Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 1987; 71: 971-2.
27. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-34.
28. Conroy T, Geoffrois L, Guillemin F, Luporsi E, Krakowski I, Spaeth D, Frasie V, Volff D. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer 1993; 72: 2190-7.
29. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004; 10: 6388S-92S.